Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
MedAssets-Precyse Adds Equation
Pamplona Capital Management is building out its healthcare data services. In November 2015, the firm spent $2.7 billion to acquire publicly traded MedAssets, Inc., which served four out of every five hospitals in the United States with technology-enabled financial products and services. Once it spun off the Spend and Clinical Resource Management segment to VHA-UHC Alliance (now called Vizient), MedAssets’ Revenue Cycle Management segment with Precyse, another portfolio company, to offer end-to-end RCM and HIM solutions. Now MedAssets-Precyse, as it’s known, is adding Equation, a Utah-based financial and clinical healthcare analytics and consulting company. Now that... Read More »CROs are back in style for M&A
Contract research organizations (CROs) are changing hands again, all over the world. Since 2010, we’ve recorded 63 transactions in total, with six announced in 2016 already. That’s a strong showing compared with five CRO deals for all of 2015, but not nearly on pace to surpass the 19 deals posted in 2014. Total combined spending, based on the 14 deals with prices disclosed, was $6.5 billion. The largest by far, at $3.9 billion, was for Pharmaceutical Product Development, acquired by then-privately held The Carlyle Group (now NASDAQ: CG). A majority of the deals (63%) were made by other CROs, compared with 16% by private equity firms, the second largest acquirer category.... Read More »eHealth Deals in Q1:16
Merger and acquisition activity edged up in the first quarter, up 17% to 35 transactions compared with the fourth quarter. The first quarter activity made up 27% of the 132 deals announced in the previous 12 months. Investor interest in this sector remains strong, particularly for revenue cycle management programs and data analytics technologies that help health care providers across the care continuum become more efficient and cut costs. Read More »Arbor Pharma Targets ‘Alcohol Use Disorder’ Drug
Specialty pharma company Arbor Pharmaceuticals has acquired XenoPort, Inc. (NASDAQ: XNPT), maker of Horizant, a potential treatment for patients with “alcohol use disorder.” XenoPort develops and commercializes a portfolio of product candidates for the treatment of neurological and other disorders in the United States. The company has entered into a clinical trial agreement with the National Institute on Alcohol Abuse and Alcoholism. Arbor will pay $7.03 per share in cash, or a total equity value of approximately $467 million. Centerview Partners is serving as exclusive financial advisor to XenoPort, and Weil, Gotshal & Manges LLP is serving as legal advisor to XenoPort.... Read More »New MainStream Adds Constellation Behavioral
Constellation Behavioral Health, LLC became the fourth healthcare services company in New MainStream Capital’s portfolio on May 19. Constellation joins Anne Arundel Dermatology, MCCI Medical Group and Suncrest Home Health. Based in Mill Valley, California, Constellation offers specialized inpatient and outpatient treatment programs for addiction, mental health and co-occurring behavioral health disorders. Founder and CEO William Morrison will retain a minority stake. Constellation operates two facilities in California: Alta Mira and Bridges to Recovery. Alta Mira is a 30-bed facility in Sausalito, California with 30,000 square feet. Bridges to Recovery is a 12-bed facility in Los... Read More »PE Firms Are Big on Dermatology
Dermatology deals are popping up like, well, you can imagine. Five acquisitions have been announced in May 2016 alone, bringing this year’s total dermatology deals to nine, and equal to the number announced in all of 2014. Those nine deals put this year on track to surpass 2015’s total of 11 deals. Private equity firms or their portfolio companies are by far the busiest players buying up dermatology clinics, accounting for 88% of acquisitions in this space since 2014. Finding a decent-size platform is a tough task in health care these days, as panelists at a recent health care deal summit noted. Outpatient physical therapy, behavioral health care, anesthesia practices are all in play. But... Read More »Recent Health Care Deals, week ending 05.20.2016
AcquirerTargetPrice Pfizer Inc. Anacor Pharmaceuticals, Inc. $5.2 billion Medtronic plcSmith & Nephew's gynecology business$350 million Welsh, Carson, Anderson & StoweInnovAge$196 million Magellan Health, Inc.Armed Forces Services Corporation$117.5 million Blue Wolf CapitalNational Home Health Care Corp.$103 million Aedifica SASaksen Weimar Care Residence$9.02 million... Read More »Medtronic’s Surgical Strikes
The Irish medical device maker Medtronic plc (NYSE: MDT) announced two strategic investments on May 18. The first wasn’t an acquisition, but could be a precursor to one. The company agreed to buy 15 next-generation robotic spinal systems from Israel-based Mazor Robotics Ltd. In addition, Medtronic will purchase newly issued securities representing 4% of Mazor’s outstanding shares for $11.9 million, and will have the opportunity to buy another 6%, plus a further 5%, in future allotments. The two companies together will promote Mazor’s spinal system, which helps surgeons plan and execute surgeries. If the initial phase of the agreement meets expectations by the end of... Read More »Pfizer: We’re So Over Allergan
Within hours after Pfizer (NYSE: PFE) and Allergan plc (NYSE: AGN) called off their $160 billion merger on April 26, 2016, Allergan announced a new acquisition. It’s taken a few weeks, but Pfizer is finally moving on. Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) is the target, based in Palo Alto, California. Anacor Pharmaceuticals focuses on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Its flagship asset is crisaborole, a differentiated non-steroidal toipcal PDE4 inhibitor with anti-inflammatory properties. Its currently under review by the FDA for the treatment of mild-to-moderate atopic dermatitis, also... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
